When is evidence of lack of harm enough? Has the rosiglitazone controversy ended?

Current Diabetes Reports

Volumn 9, Issue 5, 2009, Pages 325-328

  McCall, Anthony L ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; INSULIN; METFORMIN; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE;

ARM FRACTURE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FEMUR FRACTURE; FLUID RETENTION; FRACTURE; HEART FAILURE; HEART INFARCTION; HIP FRACTURE; HUMAN; LEG FRACTURE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; RISK BENEFIT ANALYSIS; SEX DIFFERENCE; SHORT SURVEY; SIDE EFFECT; UNSTABLE ANGINA PECTORIS;

EID: 70349734658     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-009-0063-0     Document Type: Short Survey

References (14)

1. Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457-2471.
2. Rosen CJ: The rosiglitazone story-lessons from an FDA advisory committee meeting. N Engl J Med 2007, 357:844-846.
3. Singh S, Loke YK, Furberg CD: Long-term risk of cardiovascular events with rosiglitazone: A meta-analysis. JAMA 2007, 298:1189-1195.
4. Lago RM, Singh PP, Nesto RW: Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: A meta-analysis of randomised clinical trials. Lancet 2007, 370:1129-1136.
5. Diamond GA, Bax L, Kaul S: Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med 2007, 147:578-581.
6. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE: Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials. JAMA 2007, 298:1180-1188.
7. Nesto RW, Bell D, Bonow RO, et al.: Thiazolidinedione use, fluid retention, and congestive heart failure: A consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004, 27:256-263.
8. Dormandy JA, Charbonnel B, Eckland DJ, et al.: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005, 366:1279-1289.
9. Kahn SE, Haffner SM, Heise MA, et al.: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006, 355:2427-2443.
10. Karalliedde J, Buckingham R, Starkie M, et al.: Effect of various diuretic treatments on rosiglitazone-induced fluid retention. 2006, J Am Soc Nephrol 17:3482-3490.
11. The Action to Control Cardiovascular Risk in Diabetes Study Group: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358:2545-2559.
12. ADVANCE Collaborative Group: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572.
13. BARI 2D Study Group: A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009, 360:2503-2515.
14. Retnakaran R, Zinman B: Thiazolidinediones and clinical outcomes in type 2 diabetes. Lancet 2009, 373:2088-2090.